Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Surrozen (SRZN).Invest with Confidence: Follow TipRanks' ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

BI-765845 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug ...

HHS told the Sec­ond Cir­cuit that Boehringer In­gel­heim’s vol­un­tary par­tic­i­pa­tion in Medicare ne­go­ti­a­tions “un­der­mines” its le­gal chal­lenge to the process.

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...